Tivic Health enters up to $8.4M Series B Preferred financing with Helena Global

Valion Bio, Inc.

Up to $8.4M from sale of Series B Non-Voting Convertible Preferred at $1,000/share plus warrants for common stock.
Six tranche closings: initial $700k, then $700k, then $1.75M each for four more; warrants cover 30% of underlying common.
Series B Preferred: 10% cumulative annual dividend, convertible at 90% of 5-day VWAP (floor $1.294).
Registration rights: Company to file resale registration statement within 15 days for conversion and warrant shares.
Stockholder approval required for second tranche and beyond; Exchange Cap of 19.99% of outstanding common.

item 1.01 item 5.03 item 3.02 item 3.03 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.